$CANFJun 26, 2026, 11:00 AMAI processed
Can‐Fite wins Japanese patent allowance for Namodenoson anti‐obesity use
AI Summary
Can‐Fite said the Japan Patent Office allowed a divisional application covering the use of A3 adenosine receptor agonists — explicitly including Namodenoson — to induce fat loss and treat obesity/metabolic disorders. The allowance extends Namodenoson's IP estate into Japan (on top of US, Canada, Australia, Israel) and is supported by a recent peer‐reviewed paper; Namodenoson is an oral, selective A3AR candidate with an established clinical safety database. This is an intellectual‐property milestone only — no new clinical efficacy or regulatory approvals were reported and the obesity market remains competitive (e.g., GLP‐1 therapies).
Positives
- Japan Patent Office allowed a claim covering Namodenoson/A3AR agonists for fat loss and obesity
- Adds Japan to existing patents in US, Canada, Australia and Israel, strengthening global IP
- Allowance is supported by a peer‑reviewed International Journal of Obesity paper and Namodenoson is an oral candidate with established safety data
Negatives
- Patent allowance is an IP milestone, not clinical evidence or regulatory approval
- Press release did not provide any new clinical trial efficacy or safety data for obesity
- Obesity therapeutics market is highly competitive (notably GLP‑1 class), which may limit commercial upside